Zydus Lifesciences Ltd

- The company is currently comfortable with its net debt to EBITDA ratio of around one times and does not see this as a major concern. - They continue to look for bolt-on acquisitions, particularly for their specialty 505(B)(2) franchise, implying potential for additional funding needs aligned with these acquisitions. - No explicit mention of immediate or large-scale new fundraising through debt or equity was made. - The company expects to manage capital allocation focusing on inorganic growth primarily through bolt-on acquisitions and internal cash generation. - De-leveraging plans include using cash generation to reduce net debt post acquisitions like Assertio, with ongoing monitoring of working capital and operational cash flow. - Overall, no announcement of new debt or equity fundraising was indicated in the transcript; capital strategy is balanced with growth and financial health in mind.

- FY27 capex is planned around ₹1,500 crore, reflecting an uptick due to multiple expansion initiatives. (Page 15) - Quarterly depreciation is around ₹550 crore, including capitalized licensing fees related to Mirabegron, charged until September 2027. (Page 15) - Company continues to look for bolt-on acquisitions, especially to build the Specialty 505(B)(2) franchise and expand portfolio. (Page 19, 17) - Focus on investing in new capabilities and platforms, including Specialty business scale-up and international market growth. (Page 17) - Commercialization investment for Saroglitazar (Saro) estimated at around $70 million for FY27. (Page 11) - Additional investments being made in MedTech, CDMO, and international expansion with expectations of scaling over 3-4 years. (Page 11) - Cost rationalization and efficiency improvements ongoing to offset rising costs from geopolitical and supply chain challenges. (Page 19)

- The US base business is expected to sustain a revenue base around $300-$310 million, with some erosion due to competition (e.g., Mira competition) factored in. Growth may pick up later in the year but remain balanced overall. - Specialty business, including 505(B)(2) and rare disease portfolios, is currently small but expected to scale up significantly from FY28 onwards. - International markets have shown strong growth (~40% in FY26) with broad-based momentum across regions, expected to continue in the coming years. - India formulation business is anticipated to grow 200-400 basis points faster than the market due to innovative product launches and stronger therapy focus. - Biosimilars and biologics to scale meaningfully in global markets over the next 3-4 years, with real scale-up anticipated by FY29-FY30. - Specialty oncology and supportive care portfolios in the US to grow anchored by upcoming launches and acquisitions like Assertio providing commercial scale. - Overall, expect continued double-digit growth driven by innovation, inorganic acquisitions, and expanding international presence.

- FY27 margins expected to be in excess of 24%, considering competition and Saro launch expenses. - Specialty business, including 505(B)(2) portfolio, expected to scale up notably from FY28 onwards. - Scale-up of biologics/biosimilars and international business (growing 40%+) anticipated to be key growth drivers. - Operating profit and EPS expected to improve steadily with bolt-on acquisitions and organic growth. - Medical devices business to build momentum over 3-4 years, with profitability improving via synergies. - Consumer wellness segment (Comfort Click acquisition) is a fast-growing, EPS-accretive business contributing positively. - Specialty and rare disease products currently small but projected to become more meaningful and profitable within 3-4 years. - Continued R&D focus with 8% R&D expense factored into guidance, supporting future pipeline growth.

- The current orderbook is around $300 to $310 million. - Some erosion is expected due to Mira competition, which is factored into the outlook. - The orderbook is anticipated to experience typical generic market growth trends, though pressure is expected from competition. - Specialty business contribution to the orderbook is currently small but is expected to scale up from FY28 onwards. - Overall, the $320 million pool is expected to keep growing but with some erosion from existing contracts.